Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
about
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trialTherapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinolPharmacology and Clinical Drug Candidates in Redox MedicineA new paradigm for XOR-catalyzed reactive species generation in the endotheliumMechanism of Substrate and Inhibitor Binding of Rhodobacter capsulatus Xanthine DehydrogenaseUrate-lowering therapy for gout: focus on febuxostatOIT3 deficiency impairs uric acid reabsorption in renal tubuleFunctional and Structural Characterization of Purine Nucleoside Phosphorylase from Kluyveromyces lactis and Its Potential Applications in Reducing Purine Content in FoodIdentification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanineThe role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma.Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in dog plasma and its application to a pharmacokinetic study.Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive ratsEffect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsFebuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.Febuxostat in the management of hyperuricemia and chronic gout: a review.Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductasesA sensitive LC-MS/MS method for the quantification of febuxostat in human plasma and its pharmacokinetic application.Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosisAdvances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.Screening of DUB activity and specificity by MALDI-TOF mass spectrometryXanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation.Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeuticsFebuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death.Febuxostat: a novel agent for management of hyperuricemia in gout.The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how.Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in miceXanthine oxidoreductase in respiratory and cardiovascular disorders.Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation.Uric acid secretion from adipose tissue and its increase in obesity3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo.Febuxostat: a new treatment for hyperuricaemia in gout.
P2860
Q21195361-2E5A7986-1B1D-45B2-ADA2-4B83615C1004Q24652967-A37D20EA-1CAA-46BB-A233-1CB0746B9D98Q26785525-ECD6937D-B142-461D-BFBE-D376B17E35A9Q26796264-97BFCC38-9A1E-4C78-AB11-A8682FED157BQ27653269-0C315BC3-6B42-4F83-9896-5648E9036455Q28283310-02BC2F64-906B-4A7E-8D3B-CCE3BE4FD1C3Q28509003-452B454D-D0C3-4019-8B77-450F00C62E0AQ28552877-0FACF290-F367-484C-B750-C5BEDA78C348Q30392711-532D35C5-13BF-4975-B100-BFAA297B5D18Q33634704-B26E0E89-FF38-4287-B92B-93C3DD8FDA85Q34019336-FDCAFC56-5BD2-4E5A-9EBF-1D5884255D3DQ34029936-B72E9A15-9C10-4A1C-81AB-EEF21E4D7B40Q34204854-8DD6E916-7F37-418D-954F-05C1074E4573Q34279495-C3B4F351-F8B8-416A-90DD-AD3B862FE147Q34317925-9353E77F-E34D-476E-BADD-730D2D505179Q34572852-3ACAC13A-96C7-4762-BF34-921C9DDF3444Q34581053-0BD09DE7-7024-47D3-8545-41DFAEED54B4Q34584089-1A5033A9-6BA3-4736-9B89-70939FABB6C9Q34657910-F752AED9-4501-40DF-9A4D-AAA54238AB10Q34658300-11EAD3B1-CB60-4D4A-871A-74FE5F6EA7B1Q34663374-C2346E1D-D90A-46D6-AD43-826ABE020074Q34754735-E476E70D-4F9F-4FBB-B2EC-CDB25A461F75Q34949303-FCD656B8-5989-4B94-99F1-C15C25EF9A54Q35026721-C6D5288B-C1F8-4307-B994-005092853ECCQ35232335-B19C0A81-6CEB-4E8B-B029-89DA2AF9A196Q35247002-DBE7E503-0A1F-481E-B0F8-9A8D71B63E0DQ35578918-C8722C86-E325-4C77-90F4-C61AE69D8F28Q36196489-F04033ED-776E-474D-BE72-2EF72A6DC2FDQ36291554-15E4E73F-48BC-4A97-BA03-58C03643245AQ36345980-5C7B5543-3848-49D8-B2FA-CC53C5605EA8Q36779141-B101BD76-8476-4175-842C-0705A9D82712Q36997192-052333F9-AF04-4EFC-8A74-C95CCB7C3071Q37018125-B1DAD9B1-5C3B-4120-A287-7AB65B6887BCQ37029569-0FF6E210-A941-48C5-AB7A-F516F66D52FAQ37111434-52099430-5739-4FC9-AE9C-BE76236533DDQ37133541-B44966B7-0701-446C-AE13-D66155B3DE83Q37189456-3201379E-4E6E-4495-89D7-04E26649384CQ37277498-F5242B44-C727-4C30-8361-FFAFBEFDDF86Q37384656-8B3A5156-3CA7-47A8-9CC4-BD67D22B26BBQ37485326-C5C07269-B7D8-476C-8ABB-38BC841C647D
P2860
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Selectivity of febuxostat, a n ...... xidase/xanthine dehydrogenase.
@ast
Selectivity of febuxostat, a n ...... xidase/xanthine dehydrogenase.
@en
type
label
Selectivity of febuxostat, a n ...... xidase/xanthine dehydrogenase.
@ast
Selectivity of febuxostat, a n ...... xidase/xanthine dehydrogenase.
@en
prefLabel
Selectivity of febuxostat, a n ...... xidase/xanthine dehydrogenase.
@ast
Selectivity of febuxostat, a n ...... xidase/xanthine dehydrogenase.
@en
P2093
P1433
P1476
Selectivity of febuxostat, a n ...... xidase/xanthine dehydrogenase.
@en
P2093
Hideki Horiuchi
Kumiko Hase-Aoki
Michael A Becker
Shiro Kondo
Yasuhiro Takano
Yoshinori Kasahara
P304
P356
10.1016/J.LFS.2004.10.031
P407
P577
2005-01-18T00:00:00Z